|
2024-12-30 |
2024-12-30 |
S
Sale
|
Tyree James L
Non-Executive Director
|
3,460
-7.0%
2.46
USD 8,512
|
3,460
-7.0%
|
2.46
|
USD 8,512
|
|
|
2024-12-18 |
2024-12-16 |
PS
Planned sale
|
Zak Lourie S.
Chief Financial Officer
Officer
|
2,103
-4.9%
2.34
USD 4,921
|
2,103
-4.9%
|
2.34
|
USD 4,921
|
|
|
2024-12-18 |
2024-12-16 |
PS
Planned sale
|
Smalling Ralph
Head of Regulatory
Officer
|
2,510
-13.3%
2.34
USD 5,873
|
2,510
-13.3%
|
2.34
|
USD 5,873
|
|
|
2024-12-18 |
2024-12-16 |
S
Sale
|
Cappello Joseph
VP, Pharmaceutical Development
Officer
|
6,300
-30.1%
2.34
USD 14,742
|
6,300
-30.1%
|
2.34
|
USD 14,742
|
|
|
2024-12-18 |
2024-12-16 |
PS
Planned sale
|
Zindrick Thomas
President and CEO
Executive Director
|
14,315
-27.7%
2.34
USD 33,497
|
14,315
-27.7%
|
2.34
|
USD 33,497
|
|
|
2024-09-13 |
2024-09-13 |
S
Sale
|
Szalay Aladar
Large shareholder
|
33,080
-5.2%
2.57
USD 84,946
|
33,080
-5.2%
|
2.57
|
USD 84,946
|
|
|
2024-09-13 |
2024-09-12 |
S
Sale
|
Szalay Aladar
Large shareholder
|
31,777
-4.8%
2.73
USD 86,732
|
31,777
-4.8%
|
2.73
|
USD 86,732
|
|
|
2024-09-12 |
2024-09-11 |
PS
Planned sale
|
Tyree James L
Non-Executive Director
|
1,730
-3.5%
2.60
USD 4,499
|
1,730
-3.5%
|
2.60
|
USD 4,499
|
|
|
2024-09-11 |
2024-09-11 |
S
Sale
|
Szalay Aladar
Large shareholder
|
31,376
-4.5%
2.62
USD 82,227
|
31,376
-4.5%
|
2.62
|
USD 82,227
|
|
|
2024-09-11 |
2024-09-10 |
S
Sale
|
Szalay Aladar
Large shareholder
|
20,384
-2.8%
2.51
USD 51,182
|
20,384
-2.8%
|
2.51
|
USD 51,182
|
|
|
2024-09-11 |
2024-09-09 |
S
Sale
|
Szalay Aladar
Large shareholder
|
23,383
-3.2%
2.70
USD 63,200
|
23,383
-3.2%
|
2.70
|
USD 63,200
|
|
|
2024-09-06 |
2024-09-03 |
S
Sale
|
Szalay Aladar
Large shareholder
|
42,818
-5.5%
2.09
USD 89,614
|
42,818
-5.5%
|
2.09
|
USD 89,614
|
|
|
2024-08-30 |
2024-08-30 |
S
Sale
|
Szalay Aladar
Large shareholder
|
142,589
-15.4%
2.17
USD 309,846
|
142,589
-15.4%
|
2.17
|
USD 309,846
|
|
|
2024-08-30 |
2024-08-29 |
S
Sale
|
Szalay Aladar
Large shareholder
|
107,045
-10.4%
1.98
USD 211,960
|
107,045
-10.4%
|
1.98
|
USD 211,960
|
|
|
2024-08-30 |
2024-08-28 |
S
Sale
|
Szalay Aladar
Large shareholder
|
15,918
-1.5%
2.05
USD 32,605
|
15,918
-1.5%
|
2.05
|
USD 32,605
|
|
|
2024-08-27 |
2024-08-27 |
S
Sale
|
Szalay Aladar
Large shareholder
|
51,630
-4.7%
2.11
USD 108,862
|
51,630
-4.7%
|
2.11
|
USD 108,862
|
|
|
2024-08-27 |
2024-08-23 |
S
Sale
|
Szalay Aladar
Large shareholder
|
40,000
-3.5%
2.29
USD 91,416
|
40,000
-3.5%
|
2.29
|
USD 91,416
|
|
|
2024-07-08 |
2024-06-24 |
S
Sale
|
Yu Yong
VP, Clinical Trial Operations
Officer
|
6,849
-38.7%
2.12
USD 14,520
|
6,849
-38.7%
|
2.12
|
USD 14,520
|
|
|
2024-07-08 |
2024-06-24 |
S
Sale
|
Jewett Caroline
Head of Quality
Officer
|
4,961
-23.5%
2.12
USD 10,517
|
4,961
-23.5%
|
2.12
|
USD 10,517
|
|
|
2024-07-08 |
2024-06-24 |
PS
Planned sale
|
Ryder Sean
General Counsel
Officer
|
5,496
-22.1%
2.12
USD 11,652
|
5,496
-22.1%
|
2.12
|
USD 11,652
|
|
|
2024-05-15 |
2024-05-15 |
S
Sale
|
Szalay Aladar
Large shareholder
|
17,094
-1.5%
3.66
USD 62,624
|
17,094
-1.5%
|
3.66
|
USD 62,624
|
|
|
2024-05-15 |
2024-05-14 |
S
Sale
|
Szalay Aladar
Large shareholder
|
15,426
-1.3%
3.58
USD 55,274
|
15,426
-1.3%
|
3.58
|
USD 55,274
|
|
|
2024-05-15 |
2024-05-13 |
S
Sale
|
Szalay Aladar
Large shareholder
|
3,446
-0.3%
3.62
USD 12,478
|
3,446
-0.3%
|
3.62
|
USD 12,478
|
|
|
2024-05-09 |
2024-05-08 |
S
Sale
|
Szalay Aladar
Large shareholder
|
13,919
-1.2%
3.82
USD 53,189
|
13,919
-1.2%
|
3.82
|
USD 53,189
|
|
|
2024-05-09 |
2024-05-07 |
S
Sale
|
Szalay Aladar
Large shareholder
|
6,025
-0.5%
3.67
USD 22,111
|
6,025
-0.5%
|
3.67
|
USD 22,111
|
|
|
2024-05-01 |
2024-05-01 |
S
Sale
|
Szalay Aladar
Large shareholder
|
33,061
-2.7%
3.30
USD 109,161
|
33,061
-2.7%
|
3.30
|
USD 109,161
|
|
|
2024-05-01 |
2024-04-30 |
S
Sale
|
Szalay Aladar
Large shareholder
|
20,535
-1.6%
3.12
USD 63,981
|
20,535
-1.6%
|
3.12
|
USD 63,981
|
|
|
2024-05-01 |
2024-04-29 |
S
Sale
|
Szalay Aladar
Large shareholder
|
6,403
-0.5%
3.25
USD 20,792
|
6,403
-0.5%
|
3.25
|
USD 20,792
|
|
|
2024-04-24 |
2024-04-24 |
S
Sale
|
Szalay Aladar
Large shareholder
|
8,064
-0.6%
3.50
USD 28,251
|
8,064
-0.6%
|
3.50
|
USD 28,251
|
|
|
2024-04-24 |
2024-04-23 |
S
Sale
|
Szalay Aladar
Large shareholder
|
22,000
-1.7%
3.49
USD 76,800
|
22,000
-1.7%
|
3.49
|
USD 76,800
|
|
|
2024-04-24 |
2024-04-22 |
S
Sale
|
Szalay Aladar
Large shareholder
|
14,331
-1.1%
3.53
USD 50,597
|
14,331
-1.1%
|
3.53
|
USD 50,597
|
|
|
2024-04-18 |
2024-04-17 |
S
Sale
|
Szalay Aladar
Large shareholder
|
22,737
-1.7%
3.71
USD 84,425
|
22,737
-1.7%
|
3.71
|
USD 84,425
|
|
|
2024-04-18 |
2024-04-16 |
S
Sale
|
Szalay Aladar
Large shareholder
|
48,683
-3.5%
3.53
USD 171,802
|
48,683
-3.5%
|
3.53
|
USD 171,802
|
|
|
2023-12-18 |
2023-12-15 |
S
Sale
|
Yu Yong
VP, Clinical Trial Operations
Officer
|
5,803
-100.0%
14.18
USD 82,265
|
5,803
-100.0%
|
14.18
|
USD 82,265
|
|
|
2023-12-18 |
2023-12-15 |
S
Sale
|
Yu Yong
VP, Clinical Trial Operations
Officer
|
26,732
-82.2%
12.94
USD 345,915
|
26,732
-82.2%
|
12.94
|
USD 345,915
|
|
|
2023-12-14 |
2023-12-13 |
S
Sale
|
Thomas John
Non-Executive Director
|
1,927
-0.4%
13.93
USD 26,839
|
1,927
-0.4%
|
13.93
|
USD 26,839
|
|
|
2023-12-14 |
2023-12-13 |
S
Sale
|
Thomas John
Non-Executive Director
|
7,073
-1.5%
13.23
USD 93,548
|
7,073
-1.5%
|
13.23
|
USD 93,548
|
|
|
2023-12-14 |
2023-12-13 |
S
Sale
|
Tyree James L
Non-Executive Director
|
3,347
-49.2%
13.73
USD 45,963
|
3,347
-49.2%
|
13.73
|
USD 45,963
|
|
|
2023-12-14 |
2023-12-13 |
S
Sale
|
Tyree James L
Non-Executive Director
|
5,653
-45.4%
12.91
USD 73,006
|
5,653
-45.4%
|
12.91
|
USD 73,006
|
|
|
2023-12-08 |
2023-12-07 |
S
Sale
|
Yu Yong
VP, Clinical Trial Operations
Officer
|
36,800
-53.1%
11.85
USD 435,995
|
36,800
-53.1%
|
11.85
|
USD 435,995
|
|
|
2023-11-22 |
2023-11-21 |
S
Sale
|
Yu Yong
VP, Clinical Trial Operations
Officer
|
18,665
-21.2%
10.26
USD 191,555
|
18,665
-21.2%
|
10.26
|
USD 191,555
|
|
|
2023-11-21 |
2023-11-20 |
S
Sale
|
Yu Yong
VP, Clinical Trial Operations
Officer
|
14,594
-14.2%
11.26
USD 164,261
|
14,594
-14.2%
|
11.26
|
USD 164,261
|
|
|
2023-11-21 |
2023-11-17 |
S
Sale
|
Yu Yong
VP, Clinical Trial Operations
Officer
|
3,541
-3.3%
13.04
USD 46,170
|
3,541
-3.3%
|
13.04
|
USD 46,170
|
|
|
2023-10-26 |
2023-10-25 |
S
Sale
|
Szalay Aladar
Large shareholder
|
5,704
-0.4%
19.40
USD 110,638
|
5,704
-0.4%
|
19.40
|
USD 110,638
|
|
|
2023-10-25 |
2023-10-24 |
PS
Planned sale
|
Yu Yong
VP, Clinical Trial Operations
Officer
|
5,200
-4.7%
19.11
USD 99,351
|
5,200
-4.7%
|
19.11
|
USD 99,351
|
|
|
2023-10-25 |
2023-10-23 |
S
Sale
|
Szalay Aladar
Large shareholder
|
49,987
-3.5%
19.97
USD 998,365
|
49,987
-3.5%
|
19.97
|
USD 998,365
|
|
|
2023-10-16 |
2023-10-16 |
PS
Planned sale
|
Thomas John
Non-Executive Director
|
881
-0.2%
21.30
USD 18,769
|
881
-0.2%
|
21.30
|
USD 18,769
|
|
|
2023-10-16 |
2023-10-16 |
PS
Planned sale
|
Thomas John
Non-Executive Director
|
2,452
-0.5%
20.50
USD 50,269
|
2,452
-0.5%
|
20.50
|
USD 50,269
|
|
|
2023-10-11 |
2023-10-10 |
PS
Planned sale
|
Yu Yong
VP, Clinical Trial Operations
Officer
|
400
-0.4%
22.91
USD 9,162
|
400
-0.4%
|
22.91
|
USD 9,162
|
|
|
2023-10-11 |
2023-10-10 |
PS
Planned sale
|
Yu Yong
VP, Clinical Trial Operations
Officer
|
4,800
-4.3%
21.94
USD 105,300
|
4,800
-4.3%
|
21.94
|
USD 105,300
|
|
|
2023-10-10 |
2023-10-05 |
S
Sale
|
Szalay Aladar
Large shareholder
|
985
-0.1%
25.47
USD 25,090
|
985
-0.1%
|
25.47
|
USD 25,090
|
|
|
2023-10-10 |
2023-10-05 |
S
Sale
|
Szalay Aladar
Large shareholder
|
13,266
-0.9%
24.89
USD 330,139
|
13,266
-0.9%
|
24.89
|
USD 330,139
|
|
|
2023-10-04 |
2023-10-03 |
S
Sale
|
Szalay Aladar
Large shareholder
|
75,690
-5.0%
25.49
USD 1,929,225
|
75,690
-5.0%
|
25.49
|
USD 1,929,225
|
|
|
2023-09-29 |
2023-09-28 |
S
Sale
|
Szalay Aladar
Large shareholder
|
2,289
-0.2%
24.12
USD 55,211
|
2,289
-0.2%
|
24.12
|
USD 55,211
|
|
|
2023-09-29 |
2023-09-27 |
S
Sale
|
Szalay Aladar
Large shareholder
|
11,257
-0.7%
24.47
USD 275,459
|
11,257
-0.7%
|
24.47
|
USD 275,459
|
|
|
2023-09-27 |
2023-09-26 |
PS
Planned sale
|
Yu Yong
VP, Clinical Trial Operations
Officer
|
2,203
-2.0%
24.46
USD 53,890
|
2,203
-2.0%
|
24.46
|
USD 53,890
|
|
|
2023-09-27 |
2023-09-26 |
PS
Planned sale
|
Yu Yong
VP, Clinical Trial Operations
Officer
|
1,114
-1.0%
23.51
USD 26,195
|
1,114
-1.0%
|
23.51
|
USD 26,195
|
|
|
2023-09-27 |
2023-09-26 |
PS
Planned sale
|
Yu Yong
VP, Clinical Trial Operations
Officer
|
1,883
-1.7%
22.54
USD 42,442
|
1,883
-1.7%
|
22.54
|
USD 42,442
|
|
|
2023-09-27 |
2023-09-26 |
S
Sale
|
Szalay Aladar
Large shareholder
|
9,600
-0.6%
24.51
USD 235,296
|
9,600
-0.6%
|
24.51
|
USD 235,296
|
|
|
2023-09-27 |
2023-09-26 |
S
Sale
|
Szalay Aladar
Large shareholder
|
12,740
-0.8%
24.03
USD 306,142
|
12,740
-0.8%
|
24.03
|
USD 306,142
|
|
|
2023-09-27 |
2023-09-26 |
S
Sale
|
Szalay Aladar
Large shareholder
|
7,465
-0.5%
22.47
USD 167,739
|
7,465
-0.5%
|
22.47
|
USD 167,739
|
|
|
2023-09-27 |
2023-09-25 |
S
Sale
|
Szalay Aladar
Large shareholder
|
1,100
-0.1%
27.81
USD 30,591
|
1,100
-0.1%
|
27.81
|
USD 30,591
|
|
|
2023-09-27 |
2023-09-25 |
S
Sale
|
Szalay Aladar
Large shareholder
|
1,900
-0.1%
26.60
USD 50,540
|
1,900
-0.1%
|
26.60
|
USD 50,540
|
|
|
2023-09-27 |
2023-09-25 |
S
Sale
|
Szalay Aladar
Large shareholder
|
5,511
-0.4%
25.75
USD 141,908
|
5,511
-0.4%
|
25.75
|
USD 141,908
|
|
|
2023-09-27 |
2023-09-25 |
S
Sale
|
Szalay Aladar
Large shareholder
|
3,947
-0.3%
24.82
USD 97,965
|
3,947
-0.3%
|
24.82
|
USD 97,965
|
|
|
2023-09-25 |
2023-09-22 |
S
Sale
|
Szalay Aladar
Large shareholder
|
4,621
-0.3%
27.76
USD 128,270
|
4,621
-0.3%
|
27.76
|
USD 128,270
|
|
|
2023-09-25 |
2023-09-22 |
S
Sale
|
Szalay Aladar
Large shareholder
|
4,421
-0.3%
26.88
USD 118,853
|
4,421
-0.3%
|
26.88
|
USD 118,853
|
|
|
2023-09-25 |
2023-09-21 |
S
Sale
|
Szalay Aladar
Large shareholder
|
4,678
-0.3%
28.82
USD 134,815
|
4,678
-0.3%
|
28.82
|
USD 134,815
|
|
|
2023-09-25 |
2023-09-21 |
S
Sale
|
Szalay Aladar
Large shareholder
|
2,871
-0.2%
27.89
USD 80,063
|
2,871
-0.2%
|
27.89
|
USD 80,063
|
|
|
2023-09-21 |
2023-09-20 |
PS
Planned sale
|
Yu Yong
VP, Clinical Trial Operations
Officer
|
6,000
-5.4%
27.96
USD 167,786
|
6,000
-5.4%
|
27.96
|
USD 167,786
|
|
|
2023-09-21 |
2023-09-20 |
PS
Planned sale
|
Ryder Sean
General Counsel
Officer
|
10,000
-94.6%
30.00
USD 300,000
|
10,000
-94.6%
|
30.00
|
USD 300,000
|
|
|
2023-09-20 |
2023-09-19 |
S
Sale
|
Szalay Aladar
Large shareholder
|
8,247
-100.0%
27.16
USD 223,979
|
8,247
-100.0%
|
27.16
|
USD 223,979
|
|
|
2023-09-20 |
2023-09-19 |
S
Sale
|
Szalay Aladar
Large shareholder
|
23,920
-74.4%
26.21
USD 626,962
|
23,920
-74.4%
|
26.21
|
USD 626,962
|
|
|
2023-09-20 |
2023-09-18 |
S
Sale
|
Szalay Aladar
Large shareholder
|
2,927
-36.9%
24.17
USD 70,754
|
2,927
-36.9%
|
24.17
|
USD 70,754
|
|
|
2023-09-20 |
2023-09-18 |
S
Sale
|
Szalay Aladar
Large shareholder
|
27,365
-77.5%
23.20
USD 634,895
|
27,365
-77.5%
|
23.20
|
USD 634,895
|
|
